Expression of calcium-binding proteins S100A2 and S100A4 in Barrett's adenocarcinomas

Neoplasia

Volumn 8, Issue 10, 2006, Pages 843-850

  Lee, Ok Jae ^a,b   Hong, Seung Mo ^c   Razvi, Mohammad H ^a   Peng, Dunfa ^a   Powell, Steven M ^c   Smoklin, Mark ^c   Moskaluk, Christopher A ^c   El Rifai, Wael ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b Gyeongsang National University School of Medicine   (South Korea)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Adenocarcinomas; Barrett's; Overexpression; S100A proteins; Stomach

Indexed keywords

CALCIUM BINDING PROTEIN; CALVASCULIN; S100 CALCIUM BINDING PROTEIN A2; UNCLASSIFIED DRUG;

ARTICLE; BARRETT ESOPHAGUS; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; STOMACH MUCOSA; TUMOR DIFFERENTIATION;

EID: 33749869218     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06481     Document Type: Article

References (42)

1. Devesa SS, Blot WJ, and Fraumeni JF Jr (1998). Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83, 2049-2053.
2. Dulai GS, Guha S, Kahn KL, Gornbein J, and Weinstein WM (2002). Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 122, 26-33.
3. Cameron AJ, Lagergren J, Henriksson C, Nyren O, Locke GR III, and Pedersen NL (2002). Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 122, 55-59.
4. Rana PS and Johnston DA (2000). Incidence of adenocarcinoma and mortality in patients with Barrett's oesophagus diagnosed between 1976 and 1986: implications for endoscopic surveillance. Dis Esophagus 13, 28-31.
5. O'Connor JB, Falk GW, and Richter JE (1999). The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 94, 2037-2042.
6. Ferraris R, Bonelli L, Conio M, Fracchia M, Lapertosa G, and Aste H (1997). Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme. Gruppo Operativo per lo Studio delle Precancerosi Esofagee (GOSPE). Eur J Gastroenterol Hepatol 9, 881-885.
7. el-Serag HB (2002). The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am 31, 421-440, (viii).
8. Todd JA, Johnston DA, and Dillon JF (2002). The changing spectrum of gastroesophageal reflux disease. Eur J Cancer Prev 11, 215-219.
9. van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, and Kuipers EJ (2005). Increasing incidence of Barrett's oesophagus in the general population. Gut 54, 1062-1066.
10. Hamilton SR, Smith RR, and Cameron JL (1988). Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol 19, 942-948.
11. Phillips RW and Wong RK (1991). Barrett's esophagus. Natural history, incidence, etiology, and complications. Gastroenterol Clin North Am 20, 791-816.
12. Blot WJ, Devesa SS, and Fraumeni JF Jr (1993). Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA 270, 1320.
13. El-Rifai W, Frierson HJ, Moskaluk C, Harper J, Petroni G, Bissonette E, Knuutila S, and Powell S (2001). Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology 121, 592-598.
14. El-Rifai W and Powell S (2002). Molecular and biologic basis of upper gastrointestinal malignancy gastric carcinoma. Surg Oncol Clin North Am 11, 273-291.
15. Heizmann CW, Fritz G, and Schafer BW (2002). S100 proteins: structure, functions and pathology. Front Biosci 7, d1356-d1368.
16. Mazzucchelli L (2002). Protein S100A4: too long overlooked by pathologists? Am J Pathol 160, 7-13.
17. Mueller A, Bachi T, Hochli M, Schafer BW, and Heizmann CW (1999). Subcellular distribution of S100 proteins in tumor cells and their relocation in response to calcium activation. Histochem Cell Biol 111, 453-459.
18. Marenholz I, Heizmann CW, and Fritz G (2004). S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 322, 1111-1122.
19. Schafer BW, Wicki R, Engelkamp D, Mattei MG, and Heizmann CW (1995). Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family. Genomics 25, 638-643.
20. Watson PH, Leygue ER, and Murphy LC (1998). Psoriasin (S100A7). Int J Biochem Cell Biol 30, 567-571.
21. El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ, Frierson HF Jr, and Powell SM (2002). Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 62, 6823-6826.
22. Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC, Ratschiller D, Gugger M, Donovan M, Lasek A, et al. (2002). Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 21, 7749-7763.
23. Imazawa M, Hibi K, Fujitake S, Kodera Y, Ito K, Akiyama S, and Nakao A (2005). S100A2 overexpression is frequently observed in esophageal squamous cell carcinoma. Anticancer Res 25, 1247-1250.
24. 2+ in mitotic progression of Swiss 3T3 fibroblasts. J Cell Biol 111, 183-196.
25. Feng G, Xu X, Youssef EM, and Lotan R (2001). Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. Cancer Res 61, 7999-8004.
26. Nagy N, Brenner C, Markadieu N, Chaboteaux C, Camby I, Schafer BW, Pochet R, Heizmann CW, Salmon I, et al. (2001). S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. Lab Invest 81, 599-612.
27. 2+-binding S100A2 protein is differentially expressed in epithelial tissue of glandular or squamous origin. Histol Histopathol 17, 123-130.
28. Hough CD, Cho KR, Zonderman AB, Schwartz DR, and Morin PJ (2001). Coordinately up-regulated genes in ovarian cancer. Cancer Res 61, 3869-3876.
29. Rudland PS, Platt-Higgins A, Renshaw C, West CR, Winstanley JH, Robertson L, and Barraclough R (2000). Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res 60, 1595-1603.
30. Hibi K, Fujitake S, Takase T, Kodera Y, Ito K, Akiyama S, Shirane M, and Nakao A (2003). Identification of S100A2 as a target of the DeltaNp63 oncogenic pathway. Clin Cancer Res 9, 4282-4285.
31. Matsubara D, Niki T, Ishikawa S, Goto A, Ohara E, Yokomizo T, Heizmann CW, Aburatani H, Moriyama S, et al. (2005). Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci 96, 844-857.
32. Deshpande R, Woods TL, Fu J, Zhang T, Stoll SW, and Elder JT (2000). Biochemical characterization of S100A2 in human keratinocytes: subcellular localization, dimerization, and oxidative cross-linking. J Invest Dermatol 115, 477-485.
33. Mandinova A, Atar D, Schafer BW, Spiess M, Aebi U, and Heizmann CW (1998). Distinct subcellular localization of calcium binding S100 proteins in human smooth muscle cells and their relocation in response to rises in intracellular calcium. J Cell Sci 111 (Pt 14), 2043-2054.
34. Moore BW (1965). A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 19, 739-744.
35. Mueller A, Schafer BW, Ferrari S, Weibel M, Makek M, Hochli M, and Heizmann CW (2005). The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J Biol Chem 280, 29186-29193.
36. Cho YG, Nam SW, Kim TY, Kim YS, Kim CJ, Park JY, Lee JH, Kim HS, Lee JW, et al. (2003). Overexpression of S100A4 is closely related to the aggressiveness of gastric cancer. APMIS 111, 539-545.
37. Lee WY, Su WC, Lin PW, Guo HR, Chang TW, and Chen HH (2004). Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. Oncology 66, 429-438.
38. Gongoll S, Peters G, Mengel M, Piso P, Klempnauer J, Kreipe H, and von Wasielewski R (2002). Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology 123, 1478-1484.
39. Kimura K, Endo Y, Yonemura Y, Heizmann CW, Schafer BW, Watanabe Y, and Sasaki T (2000). Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol 16, 1125-1131.
40. Nakamura T, Ajiki T, Murao S, Kamigaki T, Maeda S, Ku Y, and Kuroda Y (2002). Prognostic significance of S100A4 expression in gallbladder cancer. Int J Oncol 20, 937-941.
41. Grigorian M, Andresen S, Tulchinsky E, Kriajevska M, Carlberg C, Kruse C, Cohn M, Ambartsumian N, Christensen A, et al. (2001). Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction. J Biol Chem 276, 22699-22708.
42. Kriajevska MV, Cardenas MN, Grigorian MS, Ambartsumian NS, Georgiev GP, and Lukanidin EM (1994). Non-muscle myosin heavy chain as a possible target for protein encoded by metastasis-related mts-1 gene. J Biol Chem 269, 19679-19682.